Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 527-530

  Chen, Xue Hui ^a   Li, Zhi Qiang ^a   Peng, Hua ^a   Jin, Su Mei ^a   Fu, Hui Qing ^a   Zhu, Tie Chui ^a   Weng, Xiao Gang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Hepatocellular carcinoma; Igf; Igf 1r

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HX 1162; PLACEBO; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DRUG TARGETING; EXPERIMENTAL MOUSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; MALE; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

EID: 84878604912     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S44162     Document Type: Article

References (11)

1. Klein J, Dawson LA. Hepatocellular Carcinoma Radiation Therapy: Review of Evidence and Future Opportunities. Int J Radiat Oncol Biol Phys. Epub December 6, 2012.
2. Aravalli RN, Cressman EN, Steer CJ. Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol. 2013;87(2):227-247.
3. Della Corte C, Colombo M. Surveillance for hepatocellular carcinoma. Semin Oncol. 2012;39(4):384-398.
4. Psyrri A, Arkadopoulos N, Vassilakopoulou M, Smyrniotis V, Dimitriadis G. Pathways and targets in hepatocellular carcinoma. Expert Rev Anticancer Ther. 2012;12(10):1347-1357.
5. Tovar V, Alsinet C, Villanueva A, et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol. 2010;52(4):550-559.
6. Rowinsky EK, Schwartz JD, Zojwalla N, et al. Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancers. Curr Drug Targets. 2011; 12(14):2016-2033.
7. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res. 2007; 13(18 Pt 2):5549s-5555s.
8. Karp DD, Paz-Ares LG, Novello S, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol. 2009;27(15):2516-2522.
9. Rubin J, Ayoub N, Kaldas F, Saab S. Management of recurrent hepatocellular carcinoma in liver transplant recipients: a systematic review. Exp C lin Transplant. 2012;10(6):531-543.
10. Abu El Makarem M. An overview of biomarkers for the diagnosis of hepatocellular carcinoma. Hepat Mon. 2012;12(10 HCC):e6122.
11. Tanaka S, Arii S. Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol. 2012;39(4):486-492.